GlassScriptPhysician profile
Charlie Le
NPI 1811152465
$10,009.02
in general payments reported to CMS, 2019-2025
54 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $1,757 · 2021: $1,656 · 2022: $1,255 · 2023: $1,519 · 2024: $1,216 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,060.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,580.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,493.60 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,027.30 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $717.11 | 2019-2025 | |
| Lilly USA, LLC | $613.99 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $536.99 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $499.51 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.61 | 2019-2023 | Jardiance |
| Allergan, INC. | $440.79 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $179.61 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Exact Sciences Corporation | $152.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $141.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $139.23 | 2022 | |
| Abbott Laboratories | $135.14 | 2023-2025 | Freestyle Libre |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlie Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.